Tuberculosis (TB) is an infectious disease that has been a major menace to human health globally, causing millions of deaths yearly. Well-timed diagnosis and treatment are an arch to full recovery of the patient. Computer-aided diagnosis (CAD) has been a hopeful choice for TB diagnosis. Many CAD approaches using machine learning have been applied for TB diagnosis, specific to the artificial intelligence (AI) domain, which has led to the resurgence of AI in the medical field. Deep learning (DL), a major branch of AI, provides bigger room for diagnosing deadly TB disease. This review is focused on the limitations of conventional TB diagnostics and a broad description of various machine learning algorithms and their applications in TB diagnosis. Furthermore, various deep learning methods integrated with other systems such as neuro-fuzzy logic, genetic algorithm, and artificial immune systems are discussed. Finally, multiple state-of-the-art tools such as CAD4TB, Lunit INSIGHT, qXR, and InferRead DR Chest are summarized to view AI-assisted future aspects in TB diagnosis.

Predicting novel small molecule bioactivities for the target deconvolution, hit-to-lead optimization in drug discovery research, requires molecular representation. Previous reports have demonstrated that machine learning (ML) and deep learning (DL) have substantial implications in virtual screening, peptide synthesis, drug ADMET screening and biomarker discovery. These strategies can increase the positive outcomes in the drug discovery process without false-positive rates and can be achieved in a cost-effective way with a minimum duration of time by high-quality data acquisition. This review substantially discusses the recent updates in AI tools as cheminformatics application in medicinal chemistry for the data-driven decision making of drug discovery and challenges in high-quality data acquisition in the pharmaceutical industry while improving small-molecule bioactivities and properties.